DBV Technologies Flags Going Concern: $165.7M Cash, Runway Into Q3 2027
DBVT sits 23% above its 52-week low of $8.63.
Summary
DBV Technologies' Q3 2026 10-Q discloses substantial doubt about its ability to continue as a going concern, with $165.7 million in cash funding operations only into Q3 2027 while it awaits an FDA decision on its VIASKIN Peanut BLA.
Key Events · Earnings and Guidance · DBVT
-
Going-Concern Warning Disclosed
Management concluded existing cash and cash equivalents are not sufficient to fund operations for at least twelve months from issuance, so substantial doubt exists about the ability to continue as a going concern.
-
Cash of $165.7M, Runway Into Q3 2027
Cash and cash equivalents fell to $165.7 million at September 30, 2026 from $194.2 million at December 31, 2025; the company estimates this funds operations into the third quarter of 2027.
-
Cash Burn Nearly Doubles
Nine-month net cash used in operating and investing activities was $159.4 million versus $86.7 million a year earlier, and Q3 net loss widened to $64.5 million from $33.2 million.
-
BLA Submitted, 60-Day FDA Clock Running
The VIASKIN Peanut BLA for children aged 4-7 was submitted September 29, 2026 with a Priority Review request; the FDA has 60 days to decide whether it is complete for review, after which a PDUFA date is expected.
Analysis · DBVT · Life Sciences
DBV's Q3 10-Q carries a substantial-doubt going-concern conclusion: management says the $165.7 million of cash and equivalents at September 30, 2026 funds operations only into the third quarter of 2027, short of the twelve-month threshold from issuance. That matters because the company is now spending heavily to prepare a U.S. launch of VIASKIN Peanut before any FDA approval, with nine-month operating and investing cash burn of $159.4 million versus $86.7 million a year earlier and a Q3 net loss of $64.5 million versus $33.2 million. The BLA for children aged 4-7 was submitted September 29, 2026 with a Priority Review request, so the FDA's 60-day filing decision and any PDUFA date are the events that could unlock financing on better terms. Until then, the company says it is evaluating more ATM sales, equity transactions and warrant exercises, and there is no assurance capital will be available on acceptable terms.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 38.5% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DBVT was trading at $10.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $647.1M. The 52-week trading range was $8.63 to $26.19. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.